Immunomedics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Immunomedics's estimated revenue is currently $34.6M per year.
- Immunomedics received $125.0M in venture funding in May 2017.
- Immunomedics's estimated revenue per employee is $96821
- Immunomedics has 357 Employees.
- Immunomedics grew their employee count by 27% last year.
- Immunomedics currently has 22 job openings.
|Joseph Amalraj||Technical Director, IT at Immunomedics Inc|
|Rahul Patel||Director, Validation & Compliance|
|Brendan Delaney||Chief Commercial Officer|
|Eugene Park||Senior Director, Head of Marketing|
|Joseph Henley||Director, Bioreactor Production|
|Karen Hummel||Director, National Accounts|
|Charles Baum||Member Board Of Directors|
|Shalin Shah||Senior Director, Pricing, Contracting, & Market Access|
|Ruchi Mallya||Associate Director, Forecasting & Analytics|
|Paul Quinn||North Central Region Business Director|
What Is Immunomedics?
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|L Oreal USA||N/A||0||N/A|
|Legend Biotech ...||$12.8M||98||227%|
12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical ...
Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid ...
Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress ...
|2015-02-09||$96.4M||Undisclosed||Goldman, Sachs & Co.||Article|
Immunomedics Executive Hires
|2002-03-26||Terence Rugg||CMO & SVP||Article|
|2002-05-03||Ivan Horak||EVP Research & Development||Article|
|2013-09-04||Peter Pfreundschuh||CFO/VP Finance||Article|
|2015-01-07||Francois E. Wilhelm||Chief Medical Officer||Article|
|2016-06-22||Michael R. Garone||VP Finance/CFO||Article|
|2017-05-08||Michael Garone||Interim CEO||Article|
|2019-02-27||Scott Canute||executive director||Article|